Among the malignancies of the female genital organs, endometrial cancer is reckoned to have a comparatively good prognosis. The main methods of its treatment remain surgery and radiotherapy. Chemotherapy in endometrial cancer is always palliative. Over the recent decade, chemotherapy has been believed to be the proper management of endometrial cancer metastases, particularly to the lungs and the liver. The combined therapy proves to surpass the single agent therapy in terms of efficacy. Using three cytostatic agents (an anthracycline, a taxane and a platinum-based compound) results in the response rate of 73%. Combining chemo- and hormonotherapy has a similar efficacy to chemotherapy alone. In case of a disseminated disease, the key role is still attributed to gestagens. If a progression during the hormonotherapy is observed the chemotherapy should be used. However, in case of recurrence, surgery should always be taken into account.